Dermavant to Present New Data from Phase 3 Trial Program of VTAMA(r) (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress

Source :: Plus Company Updates. August 25, 2022
Publication Year :: 2022
Abstract: LONG BEACH: DERMAVANT SCIENCES has issued the following news release: Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced it will present data [...]

Subjects :: United States. Food and Drug Administration
Psoriasis -- Drug therapy
Dermatology -- Formulae, receipts, prescriptions
Drug approval
Adults
Dermatologic agents -- Product development
General interest
News, opinion and commentary
Vtama (Medication) -- Product development

Tools